Posted by Michael Wonder on 17 Jun 2025
Vanflyta is now approved in Canada specifically for adult patients with newly diagnosed FLT3-ITD positive AML
16 June 2025 - Approval based on QuANTUM-First results demonstrating Vanflyta added to chemotherapy improved overall survival
Daiichi Sankyo's Vanflyta (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia that is FMS-like tyrosine kinase 3-internal tandem duplication positive.
